Slideshow
-
Osimertinib slide 1
-
Osimertinib slide 2
-
Osimertinib slide 3
-
Osimertinib slide 4
-
Osimertinib slide 5
-
Osimertinib slide 6
-
Osimertinib slide 7
-
Osimertinib slide 8
-
Osimertinib slide 9
-
Osimertinib slide 10
-
Osimertinib slide 11
-
Osimertinib slide 12
-
Osimertinib slide 13
-
Osimertinib slide 14
-
Osimertinib slide 15
-
Osimertinib slide 16
-
Osimertinib slide 17
-
Osimertinib slide 18
-
Osimertinib slide 19
-
Osimertinib slide 20
-
Osimertinib slide 21
-
Osimertinib slide 22
-
Osimertinib slide 23
-
Osimertinib slide 24
-
Osimertinib slide 25
-
Osimertinib slide 26
-
Osimertinib slide 27
-
Osimertinib slide 28
-
Osimertinib slide 29
This slideshow reviews osimertinib (Tagrisso), indicated for HFirst-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations.
Table of Contents
Slide 4: Dosage and Administration
Slide 14: Cautions, Effects, and Interactions
Slide 22: What to Tell Your Patient
Slide 29: Reference